-
EP3953330
European procedure
Extract from the Register of European Patents
EP About this file: EP3953330
| EP3953330 - NITRILE-CONTAINING COMPOUNDS USEFUL AS ANTIVIRAL AGENTS FOR THE TREATMENT OF A CORONAVIRUS INFECTION [Right-click to bookmark this link] | |||
| Former [2022/07] | NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | ||
| [2022/27] | Status | No opposition filed within time limit Status updated on 18.08.2023 Database last updated on 21.01.2025 | |
| Former | The patent has been granted Status updated on 09.09.2022 | ||
| Former | Grant of patent is intended Status updated on 12.07.2022 | ||
| Former | Examination is in progress Status updated on 14.04.2022 | ||
| Former | Request for examination was made Status updated on 14.01.2022 | ||
| Former | The international publication has been made Status updated on 17.12.2021 | ||
| Former | unknown Status updated on 30.08.2021 | Most recent event Tooltip | 27.06.2024 | Change - lapse in a contracting state State(s) deleted from list of lapses: AL | published on 31.07.2024 [2024/31] | Applicant(s) | For all designated states Pfizer Inc. 66 Hudson Boulevard East New York, NY 10001-2192 / US | [2023/14] |
| Former [2022/41] | For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US | ||
| Former [2022/07] | For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US | Inventor(s) | 01 /
OWEN, Dafydd Rhys Cambridge, Massachusetts 02139 / US | 02 /
PETTERSSON, Martin Youngjin Littleton, Massachusetts 01460 / US | 03 /
REESE, Matthew Richard Groton, Connecticut 06340 / US | 04 /
SAMMONS, Matthew Forrest Cambridge, Massachusetts 02139 / US | 05 /
TUTTLE, Jamison Bryce Cambridge, Massachusetts 02139 / US | 06 /
VERHOEST, Patrick Robert Cambridge, Massachusetts 02139 / US | 07 /
WEI, Liuqing Groton, Connecticut 06340 / US | 08 /
YANG, Qingyi Cambridge, Massachusetts 02139 / US | 09 /
YANG, Xiaojing Groton, Connecticut 06340 / US | [2022/10] | Representative(s) | Pfizer European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [2022/07] | Application number, filing date | 21758144.6 | 06.08.2021 | [2022/07] | WO2021IB57281 | Priority number, date | US202063073982P | 03.09.2020 Original published format: US 202063073982 P | US202163143435P | 29.01.2021 Original published format: US 202163143435 P | US202163170158P | 02.04.2021 Original published format: US 202163170158 P | US202163194241P | 28.05.2021 Original published format: US 202163194241 P | [2022/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021250648 | Date: | 16.12.2021 | Language: | EN | [2021/50] | Type: | A1 Application with search report | No.: | EP3953330 | Date: | 16.02.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.12.2021 takes the place of the publication of the European patent application. | [2022/07] | Type: | B1 Patent specification | No.: | EP3953330 | Date: | 12.10.2022 | Language: | EN | [2022/41] | Search report(s) | International search report - published on: | EP | 16.12.2021 | Classification | IPC: | C07D207/267, C07D403/12, C07D403/14, A61P31/14, C07D401/12, C07D497/04, A61K31/4015, A61K31/4025 | [2022/07] | CPC: |
C07D401/12 (EP,IL);
A61K31/403 (IL,KR,US);
C07D403/12 (EP,CN,IL,KR,US);
A61K31/401 (IL,US);
A61K31/4025 (KR);
A61K31/427 (IL,KR,US);
A61P31/14 (EP,CN,IL,KR,US);
C07D207/267 (EP,IL);
C07D403/14 (EP,IL);
C07D497/04 (EP,IL);
A61K2300/00 (KR);
A61K9/20 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/07] | Extension states | BA | 17.06.2022 | ME | 17.06.2022 | Validation states | MA | 17.06.2022 | MD | 17.06.2022 | TN | 17.06.2022 | Title | German: | NITRILHALTIGE VERBINDUNGEN ALS ANTIVIRAL-AGENTEN ZUR BEHANDLUNG VON EINER CORONAVIRUS INFEKTION | [2022/27] | English: | NITRILE-CONTAINING COMPOUNDS USEFUL AS ANTIVIRAL AGENTS FOR THE TREATMENT OF A CORONAVIRUS INFECTION | [2022/32] | French: | COMPOSÉS COMPRENANT UN NITRILE COMME ANTIVIRAUX POUR LE TRAITEMENT D'UNE INFECTION À CORONAVIRUS | [2022/27] |
| Former [2022/07] | NITRILHALTIGE ANTIVIRALE VERBINDUNGEN | ||
| Former [2022/07] | NITRILE-CONTAINING ANTIVIRAL COMPOUNDS | ||
| Former [2022/07] | COMPOSÉS ANTIVIRAUX CONTENANT DU NITRILE | Entry into regional phase | 11.11.2021 | National basic fee paid | 11.11.2021 | Designation fee(s) paid | 11.11.2021 | Examination fee paid | Examination procedure | 11.11.2021 | Examination requested [2022/07] | 11.11.2021 | Date on which the examining division has become responsible | 31.03.2022 | Amendment by applicant (claims and/or description) | 13.04.2022 | Despatch of a communication from the examining division (Time limit: M04) | 27.04.2022 | Reply to a communication from the examining division | 13.07.2022 | Communication of intention to grant the patent | 27.07.2022 | Fee for grant paid | 27.07.2022 | Fee for publishing/printing paid | 27.07.2022 | Receipt of the translation of the claim(s) | 03.03.2023 | Observations by third parties | Divisional application(s) | EP22198597.1 / EP4166539 | EP24203045.0 | Opposition(s) | 13.07.2023 | No opposition filed within time limit [2023/38] |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | MC | 12.10.2022 | SM | 12.10.2022 | [2024/31] |
| Former [2024/16] | AL | 12.10.2022 | |
| MC | 12.10.2022 | ||
| SM | 12.10.2022 | ||
| Former [2023/37] | AL | 12.10.2022 | |
| SM | 12.10.2022 | ||
| Former [2023/33] | SM | 12.10.2022 | Cited in | International search | [YD]WO2005113580 (PFIZER [US], et al); | by applicant | WO2005113580 | US9884876 |